Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Q-PlexTM Human Cytokine Panel 1 (6-plex)

  • Regulatory status:RUO
  • Type:Multiplex Assays
  • Other names:IL-1ß, Catabolin
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RQS115249HU 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Multiplex Assays

Applications

Serum, Plasma, Cell culture supernatant

Sample Requirements

50 µl/well for all six alytes in the panel

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date.

Calibration Range

  • IL-1β : 10000 - 13.72 pg/ml
  • IL-6 : 3000 - 4.11 pg/ml
  • TNFα : 4000 - 5.49 pg/ml
  • IFNγ : 8000 - 10.97 pg/ml
  • IL-1α : 4000 – 5.5 pg/ml
  • IL-10 : 3000 - 4.11 pg/ml Actual values may vary from kit to kit. Please see the antigen card included in your kit for specific values.

Limit of Detection

  • IL-1β : 10.14 pg/ml
  • IL-6 : 3.47 pg/ml
  • TNFα : 5.20 pg/ml
  • IFNγ : 4.95 pg/ml
  • IL-1α : 5.43 pg/ml
  • IL-10 : 4.10 pg/ml
Summary

Features

  • For research use only
  • Detection Method: Chemiluminescent
  • Analytes: (IL-1β, IL-6, TNFα, IFN-γ, IL-1α, IL-10
  • This kit is validated for use with plasma, serum, and cell culture supernates

Research topic

Cytokines and chemokines and related molecules, Oncology, Energy metabolism and body weight regulation, Sepsis

Summary

The multiplexed ELISA kits, called Q-Plex™ measure the concentration of multiple proteins in each sample. Quantify cytokines, chemokines, hormones, and other common disease indicating proteins with standard or custom kits. Q-Plex Arrays are built by printing nano spots in defined arrays of multiple distinct capture antibodies in each well of a multiwell plate. Multiplexed ELISAs maximize data generation from each sample, and provide a low cost per data point.

Traditional Enzyme-Linked Immunosorbent assays (ELISA), have been used for decades in research and development, disease diagnosis and other critical fields in science. Multiplexed ELISAs offer the same time proven reliability with updated efficiency. Mutliplexed ELISAs have been developed to provide the sensitivity of ELISA with the ability to test for multiple analytes at the same time. With Q-Plex scientists can measure up to 25 distinct analytes in each well of a 96-well plate.

The Q-Plex Human Cytokine Panel 1 (6-Plex) is a fully quantitative ELISA-based chemiluminescent assay allowing concurrent measurement of six biomarkers or analytes (IL-1β, IL-6, TNFα, IFN-γ, IL-1α, IL-10). Each kit contains a 96-well plate, with each well featuring the relevant biomarker panel, and all the reagents required to perform testing. Q-Plex plates are built by absorbing six distinct capture antibodies in a defined array to the bottom of each well. Our high-quality reagents help ensure the accuracy of your results. Using just 50 µl of sample per well, up to 80 samples can be assayed for all six markers in the panel in 2.5 hours. Q-Plex Arrays provide scientists with an easy-to-use and cost-effective means of generating a cytokine profile for each sample

References to Summary

References to Interleukin-1 beta

  • Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 Aug;5 (8):629-40
  • Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep;25 (3):387-408
  • Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004 Apr;3 (4):330-9
  • Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008 Jan;4 (1):34-42
  • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50
  • Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998 Sep 29;856:1-11
  • Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87 (6):2095-147
  • Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004 Aug;4 (4):378-85
  • Eder C. Mechanisms of interleukin-1beta release. Immunobiology. 2009;214 (7):543-53
  • Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M. Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol. 2009 Nov;36 (11):922-7
  • Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol. 1997 Jan;27 (1):262-7
  • Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011 Aug;22 (4):189-95
  • Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther. 2009 Sep;9 (9):1177-88
  • Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985 Sep;28 (9):1039-46
  • Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 1985 Aug;40 (6):424-9
  • Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010 Feb 26;6 (2):e1000661
  • Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014 Jan;10 (1):44-56
  • Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr 30;356 (6372):768-74
  • Tobon-Arroyave SI, Jaramillo-Gonzalez PE, Isaza-Guzman DM. Correlation between salivary IL-1beta levels and periodontal clinical status. Arch Oral Biol. 2008 Apr;53 (4):346-52
  • Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 Aug;5 (8):629-40
  • Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep;25 (3):387-408
  • Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004 Apr;3 (4):330-9
  • Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008 Jan;4 (1):34-42
  • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50
  • Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998 Sep 29;856:1-11
  • Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87 (6):2095-147
  • Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004 Aug;4 (4):378-85
  • Eder C. Mechanisms of interleukin-1beta release. Immunobiology. 2009;214 (7):543-53
  • Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M. Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol. 2009 Nov;36 (11):922-7
  • Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol. 1997 Jan;27 (1):262-7
  • Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011 Aug;22 (4):189-95
  • Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther. 2009 Sep;9 (9):1177-88
  • Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985 Sep;28 (9):1039-46
  • Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 1985 Aug;40 (6):424-9
  • Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010 Feb 26;6 (2):e1000661
  • Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014 Jan;10 (1):44-56
  • Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr 30;356 (6372):768-74
  • Tobon-Arroyave SI, Jaramillo-Gonzalez PE, Isaza-Guzman DM. Correlation between salivary IL-1beta levels and periodontal clinical status. Arch Oral Biol. 2008 Apr;53 (4):346-52
  • Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 Aug;5 (8):629-40
  • Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep;25 (3):387-408
  • Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004 Apr;3 (4):330-9
  • Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008 Jan;4 (1):34-42
  • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50
  • Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998 Sep 29;856:1-11
  • Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87 (6):2095-147
  • Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004 Aug;4 (4):378-85
  • Eder C. Mechanisms of interleukin-1beta release. Immunobiology. 2009;214 (7):543-53
  • Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M. Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol. 2009 Nov;36 (11):922-7
  • Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol. 1997 Jan;27 (1):262-7
  • Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011 Aug;22 (4):189-95
  • Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther. 2009 Sep;9 (9):1177-88
  • Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985 Sep;28 (9):1039-46
  • Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 1985 Aug;40 (6):424-9
  • Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010 Feb 26;6 (2):e1000661
  • Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014 Jan;10 (1):44-56
  • Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr 30;356 (6372):768-74
  • Tobon-Arroyave SI, Jaramillo-Gonzalez PE, Isaza-Guzman DM. Correlation between salivary IL-1beta levels and periodontal clinical status. Arch Oral Biol. 2008 Apr;53 (4):346-52
  • Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 Aug;5 (8):629-40
  • Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep;25 (3):387-408
  • Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004 Apr;3 (4):330-9
  • Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008 Jan;4 (1):34-42
  • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50
  • Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998 Sep 29;856:1-11
  • Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87 (6):2095-147
  • Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004 Aug;4 (4):378-85
  • Eder C. Mechanisms of interleukin-1beta release. Immunobiology. 2009;214 (7):543-53
  • Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M. Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol. 2009 Nov;36 (11):922-7
  • Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol. 1997 Jan;27 (1):262-7
  • Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011 Aug;22 (4):189-95
  • Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther. 2009 Sep;9 (9):1177-88
  • Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985 Sep;28 (9):1039-46
  • Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 1985 Aug;40 (6):424-9
  • Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010 Feb 26;6 (2):e1000661
  • Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014 Jan;10 (1):44-56
  • Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr 30;356 (6372):768-74
  • Tobon-Arroyave SI, Jaramillo-Gonzalez PE, Isaza-Guzman DM. Correlation between salivary IL-1beta levels and periodontal clinical status. Arch Oral Biol. 2008 Apr;53 (4):346-52
  • Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 Aug;5 (8):629-40
  • Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep;25 (3):387-408
  • Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004 Apr;3 (4):330-9
  • Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008 Jan;4 (1):34-42
  • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50
  • Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998 Sep 29;856:1-11
  • Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87 (6):2095-147
  • Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004 Aug;4 (4):378-85
  • Eder C. Mechanisms of interleukin-1beta release. Immunobiology. 2009;214 (7):543-53
  • Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M. Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol. 2009 Nov;36 (11):922-7
  • Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol. 1997 Jan;27 (1):262-7
  • Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011 Aug;22 (4):189-95
  • Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther. 2009 Sep;9 (9):1177-88
  • Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985 Sep;28 (9):1039-46
  • Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 1985 Aug;40 (6):424-9
  • Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010 Feb 26;6 (2):e1000661
  • Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014 Jan;10 (1):44-56
  • Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr 30;356 (6372):768-74
  • Tobon-Arroyave SI, Jaramillo-Gonzalez PE, Isaza-Guzman DM. Correlation between salivary IL-1beta levels and periodontal clinical status. Arch Oral Biol. 2008 Apr;53 (4):346-52
  • Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 Aug;5 (8):629-40
  • Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep;25 (3):387-408
  • Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004 Apr;3 (4):330-9
  • Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008 Jan;4 (1):34-42
  • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50
  • Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998 Sep 29;856:1-11
  • Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87 (6):2095-147
  • Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004 Aug;4 (4):378-85
  • Eder C. Mechanisms of interleukin-1beta release. Immunobiology. 2009;214 (7):543-53
  • Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M. Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol. 2009 Nov;36 (11):922-7
  • Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol. 1997 Jan;27 (1):262-7
  • Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011 Aug;22 (4):189-95
  • Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther. 2009 Sep;9 (9):1177-88
  • Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985 Sep;28 (9):1039-46
  • Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 1985 Aug;40 (6):424-9
  • Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010 Feb 26;6 (2):e1000661
  • Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014 Jan;10 (1):44-56
  • Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr 30;356 (6372):768-74
  • Tobon-Arroyave SI, Jaramillo-Gonzalez PE, Isaza-Guzman DM. Correlation between salivary IL-1beta levels and periodontal clinical status. Arch Oral Biol. 2008 Apr;53 (4):346-52
Related Products Documents